Patents by Inventor Vipulkumar Kantibhai Patel

Vipulkumar Kantibhai Patel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS
    Publication number: 20240300965
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Application
    Filed: April 25, 2024
    Publication date: September 12, 2024
    Inventors: Zehong WAN, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E. Pero, Christopher Emst Neipp, Vipulkumar Kantibhai Patel
  • Compounds
    Patent number: 11999746
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: June 4, 2024
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Zehong Wan, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel
  • Chemical compounds
    Patent number: 10793559
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: October 6, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew Anderson, Nicholas Paul Barton, Sebastien Andre Campos, Edward Paul Cannons, Anthony William James Cooper, Kenneth David Down, Kevin James Doyle, Julie Nicole Hamblin, Graham George Adam Inglis, Armelle Le Gall, Vipulkumar Kantibhai Patel, Simon Peace, Andrew Sharpe, Gemma Victoria White
  • CHEMICAL COMPOUNDS
    Publication number: 20200071311
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Application
    Filed: September 17, 2019
    Publication date: March 5, 2020
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew ANDERSON, Nicholas Paul BARTON, Sebastien Andre CAMPOS, Edward Paul CANNONS, Anthony William James COOPER, Kenneth David DOWN, Kevin James DOYLE, Julie Nicole HAMBLIN, Graham George Adam INGLIS, Armelle LE GALL, Vipulkumar Kantibhai PATEL, Simon PEACE, Andrew SHARPE, Gemma Victoria WHITE
  • COMPOUNDS
    Publication number: 20200055863
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Application
    Filed: July 29, 2019
    Publication date: February 20, 2020
    Inventors: Zehong WAN, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E. Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel
  • Chemical compounds
    Patent number: 10457674
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: October 29, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew Anderson, Nicholas Paul Barton, Sebastien Andre Campos, Edward Paul Cannons, Anthony William James Cooper, Kenneth David Down, Kevin James Doyle, Julie Nicole Hamblin, Graham George Adam Inglis, Armelle Le Gall, Vipulkumar Kantibhai Patel, Simon Peace, Andrew Sharpe, Gemma Victoria White
  • Compounds
    Patent number: 10428078
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: October 1, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Zehong Wan, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel
  • IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS
    Publication number: 20190202799
    Abstract: Compounds of formula (I) and salts thereof: wherein R1, R2, R3, a, X1, X2, X3, X4, and X5 are as defined hereinbefore. Compounds of formula (I) and salts thereof have been found to inhibit the binding of the BET family of bromodomain containing proteins to, for example, acetylated lysine residues and thus may have use in therapy, for example in the treatment of autoimmune and inflammatory diseases, such as rheumatoid arthritis; and cancers.
    Type: Application
    Filed: August 31, 2017
    Publication date: July 4, 2019
    Inventors: Andrew BAXTER, Rino Antonio BIT, John Alexander BROWN, David HIRST, Philip HUMPHREYS, Katherine Louise JONES, Vipulkumar Kantibhai PATEL
  • IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS
    Publication number: 20190175571
    Abstract: Compounds of formula (I) and salts thereof: wherein R1, R2, R3 and a are as defined herein. Compounds of formula (I) and salts thereof have been found to inhibit the binding of the BET family of bromodomain containing proteins to, for example, acetylated lysine residues and thus may have use in therapy, for example in the treatment of autoimmune and inflammatory diseases, such as rheumatoid arthritis; and cancers.
    Type: Application
    Filed: August 31, 2017
    Publication date: June 13, 2019
    Inventors: Andrew BAXTER, John Alexander BROWN, David HIRST, Philip HUMPHREYS, Katherine Louise JONES, Vipulkumar Kantibhai PATEL
  • Chemical Compounds
    Publication number: 20190161480
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Application
    Filed: August 7, 2017
    Publication date: May 30, 2019
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Sebastien Andre CAMPOS, Samuel Edward DALTON, Vipulkumar Kantibhai PATEL
  • CHEMICAL COMPOUNDS
    Publication number: 20190040051
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Application
    Filed: February 10, 2017
    Publication date: February 7, 2019
    Inventors: Niall Andrew ANDERSON, Nicholas Paul BARTON, Sebastien Andre CAMPOS, Edward Paul CANNONS, Anthony William James COOPER, Kenneth David DOWN, Kevin James DOYLE, Julie Nicole HAMBLIN, Graham George Adam INGLIS, Armelle LE GALL, Vipulkumar Kantibhai PATEL, Simon PEACE, Andrew SHARPE, Gemma Victoria WHITE
  • COMPOUNDS
    Publication number: 20190023715
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Application
    Filed: September 27, 2018
    Publication date: January 24, 2019
    Inventors: Zehong WAN, Xiaomin ZHANG, Jian WANG, Matthew Robert SENDER, Eric Steven MANAS, Raphael Anthony RIVERO, Joseph E PERO, Christopher Ernst NEIPP, Vipulkumar Kantibhai PATEL
  • Compounds
    Patent number: 10125141
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: November 13, 2018
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Zehong Wan, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel
  • 7-(1H-pyrazol-4-yl)-1,6-naphthyridine compounds as Syk inhibitors
    Patent number: 8633319
    Abstract: The present invention relates to a compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (Syk) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast and/or basophil cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory disease and/or allergic disorders, and in cancer therapy, specifically heme malignancies, chronic spontaneous urticaria and autoimmune conditions.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: January 21, 2014
    Assignee: Glaxo Group Limited
    Inventors: Francis Louis Atkinson, Michael David Barker, Clement Douault, Neil Stuart Garton, John Liddle, Vipulkumar Kantibhai Patel, Alexander George Steven Preston, David Matthew Wilson
  • PYRIDO[3,4-B]PYRAZINE DERIVATIVES AS SYK INHIBITORS
    Publication number: 20140005188
    Abstract: A compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (Syk) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory disease and/or allergic disorders, and in cancer therapy, specifically heme malignancies, and autoimmune conditions.
    Type: Application
    Filed: March 8, 2012
    Publication date: January 2, 2014
    Applicant: GLAXO GROUP LIMITED
    Inventors: Francis Louis Atkinson, Stephen John Atkinson, Michael David Barker, Clement Douault, Neil Stuart Garton, John Liddle, Vipulkumar Kantibhai Patel, Alexander G. Preston, Tracy Jane Shipley, David Matthew Wilson, Robert J. Watson
  • Pyrimidinecarboxamide derivatives as inhibitors of Syk kinase
    Patent number: 8470835
    Abstract: The present invention relates to the compound of formula (I): or a salt, preferably a pharmaceutically acceptable salt, thereof; is an inhibitor of spleen tyrosine kinase (SYK) and therefore potentially of use in treating diseases resulting from inappropriate mast cell activation, for instance allergic and inflammatory diseases, as well of potential use in cancer therapy, specifically heme malignancies.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: June 25, 2013
    Assignee: Glaxo Group Limited
    Inventors: Francis Louis Atkinson, Vipulkumar Kantibhai Patel
  • Chemical compounds
    Patent number: 8383635
    Abstract: The invention is directed to pyrido[4,3-d]pyrimidin-5(6H)-one derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R3, and R4 are defined below. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: August 12, 2009
    Date of Patent: February 26, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Francis Louis Atkinson, Jeffrey Michael Axten, Maria Cichy-Knight, Michael Lee Moore, Vipulkumar Kantibhai Patel, Xinrong Tian, Christopher Roland Wellaway, Allison K. Dunn
  • 7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS
    Publication number: 20130040984
    Abstract: The present invention relates to a compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (Syk) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast and/or basophil cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory disease and/or allergic disorders, and in cancer therapy, specifically heme malignancies, chronic spontaneous urticaria and autoimmune conditions.
    Type: Application
    Filed: April 27, 2011
    Publication date: February 14, 2013
    Applicant: GLAXO GROUP LIMITED
    Inventors: Francis Louis Atkinson, Michael David Barker, Clement Douault, Neil Stuart Garton, John Liddle, Vipulkumar Kantibhai Patel, Alexander George Steven Preston, David Matthew Wilson
  • PYRIMIDINECARBOXAMIDE DERIVATIVES AS INHIBITORS OF SYK KINASE
    Publication number: 20110275655
    Abstract: The present invention relates to the compound of formula (I): or a salt, preferably a pharmaceutically acceptable salt, thereof; is an inhibitor of spleen tyrosine kinase (SYK) and therefore potentially of use in treating diseases resulting from inappropriate mast cell activation, for instance allergic and inflammatory diseases, as well of potential use in cancer therapy, specifically heme malignancies.
    Type: Application
    Filed: January 11, 2010
    Publication date: November 10, 2011
    Applicant: GLAXO GROUP LIMITED
    Inventors: Francis Louis Atkinson, Vipulkumar Kantibhai Patel
  • CHEMICAL COMPOUNDS
    Publication number: 20110136838
    Abstract: The invention is directed to pyrido[4,3-d]pyrimidin-5(6H)-one derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R3, and R4 are defined below. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: August 12, 2009
    Publication date: June 9, 2011
    Inventors: Francis Louis Atkinson, Jeffrey Michael Axten, Maria Cichy-Knight, Michael Lee Moore, Vipulkumar Kantibhai Patel, Xinrong Tian, Christopher Roland Wellaway, Allison K. Dunn